| Indication* |
Posology |
Special dosing instructions |
Moderate to severe
Crohn’s Disease
in patients who have an inadequate response to conventional therapies.
|
IV infliximab induction with 5 mg/kg at week 0 and at week 2
SC maintenance with Remsima® 120 mg dose every 2 weeks, starting from Week 6
|
|
|
Refractory fistulising
Crohn’s Disease
|
|
|
Moderately severe to severely active
Ulcerative Colitis
in patients who have an inadequate response to conventional therapies.
|
|
Active
Ankylosing Spondylitis
|
|
Active and progressive
Psoriatic Arthritis
in patients who have responded inadequately to disease-modifying anti-rheumatic drug (DMARD) therapy.
|
May be given in combination with MTX
|
Moderate to severe
Plaque Psoriasis
for patients in whom phototherapy or conventional systemic treatments have been inadequate or are inappropriate
|
|
Rheumatoid Arthritis
- patients with active disease despite treatment with methotrexate (MTX)
- patients with active disease who have not previously received methotrexate.
|
IV induction with 3 mg/kg at week 0 and at week 2
SC maintenance with 120 mg dose every 2 weeks, starting from Week 6
|
Must be given concomitantly with MTX |
